NEW YORK (GenomeWeb News) – Response Genetics today announced an agreement with managed healthcare firm MultiPlan to provide its members with access to Response's molecular diagnostic tests.

MultiPlan has about 67 million consumers accessing its provider network products, and it contracts with more than 900,000 healthcare providers across the US, Response said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.